Tertomotide

Buy Tertomotide peptide Online at Wholesale Price. Factory Supply. Get Latest Price. Inquiry Now!
Purchase Tertomotide From Manufacturer/Supplier, For Sale, Price,Supply - Bolise.

[ Other Name ] GV1001
[ CAS NO. ] 915019-08-8
[ Molecular Formula ] C85H146N26O21
[ Molecular Weight ] 1868.26
[ Appearance ] White Powder
[ Purity ] ≥98%

[ Function ]
1. Anti-inflammatory;
2. Antioxidant;
3. Anti-apoptotic and pro-survival functions;
4. Improvement of cognitive function;

About Tertomotide
Tertomotide (CAS: 922174-60-5), also known as GV1001, is a synthetic 16-amino acid peptide derived from the catalytic site (residues 611–626) of human telomerase reverse transcriptase (hTERT). It is highly water-soluble, stable for long-term storage at -20°C in sealed conditions, and primarily utilized in scientific research. Originally developed as a therapeutic cancer vaccine, its unique multifunctionality has led to its application in diverse fields—such as neurodegenerative disease research and aging regulation—making it a focal point of interdisciplinary scientific inquiry.
A key characteristic of Tertomotide is its ability to bind to both MHC-I and MHC-II molecules, effectively activating CD4⁺ helper T cells and CD8⁺ cytotoxic T cells to induce a specific immune response against telomerase-positive tumor cells. Although clinical trial results regarding its use in combination with chemotherapy for various cancers have been mixed, preclinical studies have confirmed its significant inhibitory effects on tumor cells, such as those in pancreatic cancer and melanoma, establishing it as a valuable tool for cancer immunotherapy research.
Tertomotide can cross the blood-brain barrier and interact with intracellular chaperones HSP70 and HSP90; this interaction inhibits beta-amyloid deposition and tau protein hyperphosphorylation, thereby blocking signaling pathways associated with brain aging. Phase II clinical trials indicate a potential for improving cognitive function in patients with moderate-to-severe Alzheimer's disease—particularly regarding the preservation of language function—and Phase III trials are currently underway.
Tertomotide also exhibits anti-inflammatory activity, demonstrating protective effects in disease models such as arthritis and hearing loss, and is being investigated in clinical trials for conditions including benign prostatic hyperplasia.